Bretylium Tosylate In Plastic Container
Brand names,
Bretylium Tosylate In Plastic Container
Analogs
Bretylium Tosylate In Plastic Container
Brand Names Mixture
Bretylium Tosylate In Plastic Container
Chemical_Formula
C11H17BrN+
Bretylium Tosylate In Plastic Container
RX_link
http://www.rxlist.com/cgi/generic3/bretosy.htm
Bretylium Tosylate In Plastic Container
fda sheet
Bretylium Tosylate In Plastic Container
msds (material safety sheet)
Bretylium Tosylate In Plastic Container
Synthesis Reference
No information avaliable
Bretylium Tosylate In Plastic Container
Molecular Weight
243.163 g/mol
Bretylium Tosylate In Plastic Container
Melting Point
No information avaliable
Bretylium Tosylate In Plastic Container
H2O Solubility
Freely soluble
Bretylium Tosylate In Plastic Container
State
Solid
Bretylium Tosylate In Plastic Container
LogP
No information avaliable
Bretylium Tosylate In Plastic Container
Dosage Forms
Solution for injection (50mg/mL)
Bretylium Tosylate In Plastic Container
Indication
For use in the prophylaxis and therapy of ventricular fibrillation. Also used in the treatment of life-threatening ventricular arrhythmias, such as ventricular tachycardia, that have failed to respond to adequate doses of a first-line antiarrhythmic agent, such as lidocaine.
Bretylium Tosylate In Plastic Container
Pharmacology
Bretylium is a bromobenzyl quaternary ammonium compound which selectively accumulates in sympathetic ganglia and their postganglionic adrenergic neurons where it inhibits norepinephrine release by depressing adrenergic nerve terminal excitability. Bretylium also suppresses ventricular fibrillation and ventricular arrhythmias.
Bretylium Tosylate In Plastic Container
Absorption
No information avaliable
Bretylium Tosylate In Plastic Container
side effects and Toxicity
Oral, mouse: LD50 = 400 mg/kg. In the presence of life-threatening arrhythmias, underdosing with bretylium probably presents a greater risk to the patient than potential overdosage. However, one case of accidental overdose has been reported in which a rapidly injected intravenous bolus of 30 mg/kg was given instead of an intended 10 mg/kg dose during an episode of ventricular tachycardia. Marked hypertension resulted, followed by protracted refractory hypotension. The patient expired 18 hours later in asystole, complicated by renal failure and aspiration pneumonitis. Bretylium serum levels were 8000 ng/mL.
Bretylium Tosylate In Plastic Container
Patient Information
Bretylium Tosylate In Plastic Container
Organisms Affected
Humans and other mammals